Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

NCT00115141 | Completed Phase 2

• 1 other identifier: 1513-RESI
• Study Type: interventional
• Target: 88
• Locations: 0 countries
• Sites: N/A

Brief Summary

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks. A second purpose is to evaluate the safety of the drug.

Conditions

Warts

Keywords

Wart(s); Adults; Common Wart(s)

Outcome Measures

Primary Outcomes (1)

• Clearance of treated wart(s)

Secondary Outcomes (2)

• Partial clearance of treated wart(s)

• Wart recurrence

Interventions

Resiquimod DRUG

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of common warts
• Two forms of birth control

You may not qualify if:

• Pregnant or breast feeding
• Other types of warts, ie. plantar
• Currently participating in another clinical study
• Chronic viral hepatitis B or C

Sponsors & Collaborators

• Graceway Pharmaceuticals, LLC: lead

MeSH Terms

Conditions

Warts

Interventions

resiquimod

Condition Hierarchy (Ancestors)

Papillomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Skin Diseases, Viral; Tumor Virus Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: SINGLE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: June 21, 2005
• First Posted: June 22, 2005
• Study Start: April 1, 2004
• Last Updated: February 19, 2007

Record last verified: 2006-11